B. Kalaska

发表

Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins

D. Pawlak, S. Yusa, K. Szczubiałka, 2022, Journal of clinical medicine.

LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys.

D. Pawlak, K. Pawlak, B. Kalaska, 2018, Bone.

New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal

M. Nowakowska, W. Buczko, K. Szczubiałka, 2014 .

Preclinical Toxicity and Safety of MM-129—First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer

D. Pawlak, M. Mojzych, K. Pawlak, 2021, Pharmaceutics.

Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis.

M. Nowakowska, W. Buczko, K. Szczubiałka, 2012, European journal of pharmacology.

Elevated Levels of Peripheral Kynurenine Decrease Bone Strength in Rats with Chronic Kidney Disease

D. Pawlak, M. Brzóska, K. Pawlak, 2017, Front. Physiol..

Oxidized glycerophosphatidylcholines in diabetes through non-targeted metabolomics: Their annotation and biological meaning.

C. Barbas, A. Krętowski, M. Ciborowski, 2019, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Antithrombotic effects of pyridinium compounds formed from trigonelline upon coffee roasting.

A. Leszczyńska, A. Marcinek, W. Buczko, 2014, Journal of agricultural and food chemistry.

Modulation of the Paracrine Kynurenic System in Bone as a New Regulator of Osteoblastogenesis and Bone Mineral Status in an Animal Model of Chronic Kidney Disease Treated with LP533401

D. Pawlak, B. Cylwik, K. Pawlak, 2020, International journal of molecular sciences.

The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents

M. Nowakowska, D. Pawlak, M. Rusak, 2019, Marine drugs.

Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats

M. Nowakowska, D. Pawlak, S. Yusa, 2020, The Journal of Pharmacology and Experimental Therapeutics.

Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice

D. Pawlak, S. Yusa, K. Szczubiałka, 2021, International journal of molecular sciences.

Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models

D. Pawlak, P. Podlasz, B. Kalaska, 2021, Pharmaceutics.

Serum metabolic fingerprinting after exposure of rats to quinolinic acid.

A. Krętowski, M. Ciborowski, D. Pawlak, 2016, Journal of pharmaceutical and biomedical analysis.

The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats

D. Pawlak, Aleksandra Jakimczuk, B. Kalaska, 2022, Vaccine.

The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target

B. Musielak, M. Nowakowska, D. Pawlak, 2019, RSC advances.

Kynurenine Pathway in Chronic Kidney Disease: What’s Old, What’s New, and What’s Next?

D. Pawlak, B. Kalaska, A. Mor, 2020, International journal of tryptophan research : IJTR.

The toxicology of heparin reversal with protamine: past, present and future

B. Kalaska, J. Miklosz, A. Mogielnicki, 2016, Expert opinion on drug metabolism & toxicology.

Distributed under Creative Commons Cc-by 4.0 a Link between Central Kynurenine Metabolism and Bone Strength in Rats with Chronic Kidney Disease

D. Pawlak, M. Brzóska, K. Pawlak, 2022 .

The Toxicokinetic Profile of Dex40-GTMAC3—a Novel Polysaccharide Candidate for Reversal of Unfractionated Heparin

I. Kasacka, M. Nowakowska, D. Pawlak, 2016, Front. Pharmacol..

Monitoring of Cardiorespiratory Parameters in Rats—Validation Based on Pharmacological Stimulation

D. Pawlak, B. Kalaska, J. Miklosz, 2021, Pharmaceuticals.

Nonclinical Evaluation of Novel Cationically Modified Polysaccharide Antidotes for Unfractionated Heparin

J. Bereta, M. Nowakowska, D. Pawlak, 2015, PloS one.

The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review

B. Kalaska, J. Miklosz, A. Mogielnicki, 2023, Thrombosis Journal.

Anticoagulant Properties of Poly(sodium 2-(acrylamido)-2-methylpropanesulfonate)-Based Di- and Triblock Polymers.

M. Nowakowska, D. Pawlak, S. Yusa, 2018, Biomacromolecules.

Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.

I. Kasacka, M. Nowakowska, D. Pawlak, 2016, Translational research : the journal of laboratory and clinical medicine.

Neurobehavioral effects of uremic toxin–indoxyl sulfate in the rat model

Krzysztof Nosek, D. Pawlak, B. Kalaska, 2020, Scientific Reports.

P372Heparin binding copolymer reverses the anticoagulant activity of low molecular weight heparins: safety and efficacy data in rats

M. Nowakowska, D. Pawlak, K. Szczubiałka, 2018 .

A facile one-stone-two-birds strategy for fabricating multifunctional 3D nanofibrous scaffolds.

P. Sajkiewicz, D. Kołbuk, Altangerel Amarjargal, 2023, Biomaterials science.

Anionic and cationic block copolymers as promising modulators of blood coagulation

B. Kalaska, J. Miklosz, A. Mogielnicki, 2023, European Polymer Journal.

Metabolic profiling reveals the nutraceutical effect of Gongolaria abies-marina and Rosmarinus officinalis extracts in a type 1 diabetes animal model.

M. Ciborowski, Joanna Godzien, F. J. Rupérez, 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.